- Home
- DEA vs ELVN Comparison
DEA vs ELVN Comparison
Compare DEA & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DEA
- ELVN
- Stock Information
- Founded
- DEA 2011
- ELVN 2016
- Country
- DEA United States
- ELVN United States
- Employees
- DEA N/A
- ELVN N/A
- Industry
- DEA Real Estate Investment Trusts
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- DEA Real Estate
- ELVN Health Care
- Exchange
- DEA Nasdaq
- ELVN Nasdaq
- Market Cap
- DEA 844.3M
- ELVN 842.4M
- IPO Year
- DEA 2015
- ELVN 2020
- Fundamental
- Price
- DEA $8.10
- ELVN $17.77
- Analyst Decision
- DEA Hold
- ELVN Strong Buy
- Analyst Count
- DEA 4
- ELVN 4
- Target Price
- DEA $11.63
- ELVN $39.25
- AVG Volume (30 Days)
- DEA 1.9M
- ELVN 356.9K
- Earning Date
- DEA 04-29-2025
- ELVN 05-13-2025
- Dividend Yield
- DEA 12.07%
- ELVN N/A
- EPS Growth
- DEA N/A
- ELVN N/A
- EPS
- DEA 0.18
- ELVN N/A
- Revenue
- DEA $308,103,000.00
- ELVN N/A
- Revenue This Year
- DEA $6.87
- ELVN N/A
- Revenue Next Year
- DEA $7.97
- ELVN N/A
- P/E Ratio
- DEA $44.89
- ELVN N/A
- Revenue Growth
- DEA 5.25
- ELVN N/A
- 52 Week Low
- DEA $7.79
- ELVN $13.30
- 52 Week High
- DEA $14.53
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- DEA 33.01
- ELVN 47.25
- Support Level
- DEA $7.88
- ELVN $15.44
- Resistance Level
- DEA $8.40
- ELVN $18.14
- Average True Range (ATR)
- DEA 0.43
- ELVN 1.98
- MACD
- DEA -0.07
- ELVN 0.11
- Stochastic Oscillator
- DEA 21.88
- ELVN 63.58
About DEA Easterly Government Properties Inc.
Easterly Government Properties Inc is a real estate investment trust. It is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. The company generates all its revenue by leasing its properties to such agencies.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.